Andrii Melenchuk

Andrii Melenchuk

Real Pharm · Druha Liga · Midfielder · #14 · Ukraine · 23 yrs

Andrii Melenchuk: club Real Pharm, 13 apps · 1 G · 0 A (season, all competitions).

OverviewCareerStatisticsTransfers
A. Melenchuk photo

A. Melenchuk

Midfielder · #14

Real PharmReal PharmSeason, all competitions13 apps · 1 G · 0 APositionMidfielderAge23available

Season form, all competitions

  • 13 Apps
  • 1 Goals
  • 0 Assists
  • 1017 Minutes
  • 0.09 Goals / 90 77th percentile
  • 0 Assists / 90 50th percentile
  • 0 Shots / 90
  • 0 Key passes / match

How these metrics are calculated (v1)

Profile

Full name
Andrii Melenchuk
Age
23
Nationality
Ukraine
Height
183 cm
Weight
74 kg
Transfers
4

Statistics, all competitions

View all

Season intelligence

Box-to-box engine

Profile as Midfielder: high usage. Archetype: Box-to-box engine.

  • Finisher
  • Creator
  • Ball carrier
  • Pressure magnet
  • Defensive work
  • High usage
1Goals
0Assists
13Apps
1017′Minutes
0Shirt
Midfielder

Card attributes

What these ratings mean

Scouting profile

  • Attack8
  • Vision0
  • Control0
  • Precision0
  • Pressure0
  • Defense0
  • Engine97
  • Discipline87
  • Flair0

Derived metrics

How these metrics are calculated

Goals per 900.091 goals in 1017′
Non-penalty goals per 900.09
Starting rate77%10/13 starts
Minutes per appearance781017′ in 13 apps

Full stat breakdown

Season summary

Appearances
13
Lineups
10
Minutes
1017
Position
Midfielder
Goals
1
Assists
0
Yellow Cards
1
Red Cards
0

Appearances & minutes

Captain
No
Lineups
10
Minutes
1017
Position
Midfielder
Appearances
13

Substitute usage

In
3
Out
0
Bench
10

Goals & keepers

Total
1

Discipline

Red
0
Yellow
1
Yellowred
0

Transfers

View all
DateTypeFromTo
2026-03-09Free agentInhuletsInhulets—
2025-02-07Free TransferDinamo TiranaDinamo Tirana DINInhuletsInhulets
2025-02-07Free TransferReal PharmReal PharmInhuletsInhulets

Player headlines

No linked headlines

We haven’t matched any recent articles to this page yet. Browse the latest football news instead.

Explore more news